Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of genetic influence on response to ranibizumab vs bevacizumab in neovascular age-related macular degeneration
2019-003204-12Phase 3Active
- Sponsor
- Parc de Salut Mar
- Start
- Dec 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Lucentis arm with Avastin arm (2 arms). Primary endpoint: Visual acuity score on ETDRS or converted Snellen. Started Dec 2021; status: active.
02
Drugs
ranibizumabbevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-003204-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003204-12.